Carefully designed wet Age-Related Macular Degeneration Models.

Age-Related Macular Degeneration (AMD) has a global prevalence of around 170 million. Wet AMD, as opposed to dry AMD, exhibits vascular involvement which greatly exacerbates the pathological process of the disease. Only 10-15% of cases of AMD are wet, and while it is the more severe form, it can be treated.

AMD is one of the world’s top 7 causes of blindness and visual impairment. At PharmaLegacy, we believe that this needs to change. Were we to join efforts, with our models and your pipeline, AMD might one day lose its spot on the world’s leading causes of visual impairment and blindness.

Contact Us


Where pharmacology meets excellence:

  • AAALAC and CNAS guidelines-adherent animal studies
  • 24/7 access to PharmaLegacy representatives
  • Completed over 400 FDA / CFDA IND filings
  • FDA Part 11 compliant

Over half of the top 20 pharmaceutical companies can’t be wrong. Choose PharmaLegacy.

Contact Us

Top Pharmaceutical Companies Trust PharmaLegacy For Their Preclinical Ophthalmology Studies

Your preclinical ophthalmology studies call for flawless and affordable ophthalmology models. Download our Ophthalmology brochure and see how our models and decades of expertise can give you the clarity you need in your pipeline.


    We’re ready when you are.

    Tell us your pharmacology challenges.